Application and optimization strategy of CAR-NK in AML

In recent years, the application of immunotherapy in the field of cancer has received increasing attention, especially the new precision cellular immunotherapy CAR-T. Although CAR-T Cell therapy has made great achievements in the field of tumor treatment, it seems to show a stagnant phenomenon in the treatment of blood cancer, especially acute myeloid leukemia (AML). However, the emergence of a promising optimization scheme to CAR-T Cell therapy, CAR-NK Cell therapy, seems to break this dilemma. In terms of AML treatment, compared with CAR-T Cell therapy, CAR-NK are safer, more effective and more economical. However, it still has some shortcomings that need improvement, such as how to quickly and in bulk obtain NK cells and how to improve the effect of in vivo action. This paper discusses the benefits of CAR-NK Cell therapy compared with CAR-T Cell therapy, the application status in the AML field, the shortcomings of the method and the solutions, with AML as an example. The purpose is to apply such a very potential treatment method to more refractory diseases and benefit more patients as soon as possible.